In vivo, hyperphosphatemia and normal 1,25(OH)2-vitamin D3 levels are achieved by the administration of antibodies blocking FGF-23, which reduces urinary fractional excretion of phosphate (UFE phosphate). Here, FGF23 is linked to hyperphosphatemia.